BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) has announced its participation in three upcoming investor conferences. The company will present at the 2024 Jefferies London Healthcare Conference on November 20 at 5:00 a.m. ET, the 7th Annual Evercore HealthCONx Conference in Coral Gables on December 4 at 2:35 p.m. ET, and the Piper Sandler 36th Annual Healthcare Conference in New York on December 5 at 8:30 a.m. ET. Live audio webcasts and replays will be available through BioCryst's website investor section.

News Market Reaction – BCRX

+9.57%

+9.57% Session move

In the trading session that priced this news, BCRX gained 9.57%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

• 2024 Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 5:00 a.m. ET.
• 7^th Annual Evercore HealthCONx Conference in Coral Gables on Wednesday, December 4, 2024, at 2:35 p.m. ET.
• Piper Sandler 36^th Annual Healthcare Conference in New York on Thursday, December 5, 2024, at 8:30 a.m. ET.
  

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

When is BioCryst (BCRX) presenting at the Jefferies London Healthcare Conference 2024?

BioCryst (BCRX) will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 5:00 a.m. ET.

Which investor conferences will BioCryst (BCRX) attend in December 2024?

BioCryst (BCRX) will attend the Evercore HealthCONx Conference in Coral Gables on December 4 and the Piper Sandler Healthcare Conference in New York on December 5, 2024.

How can investors access BioCryst's (BCRX) conference presentations?

Investors can access live audio webcasts and replays of BioCryst's presentations through the Investors & Media section of the company's website at biocryst.com.